Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
11Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Tevogen Bio Holdings Inc. (TVGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
24Total relationships
4Distinct source URLs
14High confidence
0.801Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Tevogen Bio Holdings Inc. Suppliers
Ticker
Name
Confidence
Evidence
KRHP-LLC
KRHP-LLC
90%
In January 2025, the Company received a grant of $ 2.0 million from KRHP to further the Company’s development of off-the-shelf, genetically unmodified precision T cell therapeutics to treat infectiou…
SSVK
SSVK
90%
On June 15, 2024, we entered into that certain repurchase agreement with SSVK
THE-NASDAQ-STOCK-MARKET-LLC
THE-NASDAQ-STOCK-MARKET-LLC
90%
On March 20, 2026, Tevogen Bio Holdings Inc. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance…
A-G-P-ALLIANCE-GLOBAL-PARTNERS
A-G-P-ALLIANCE-GLOBAL-PARTNERS
85%
proceeds from sales of Common Stock under our Sales Agreement with A.G.P./Alliance Global Partners (the "Sales Agreement"),
CD-8-TECHNOLOGY-SERVICES-LLC
CD-8-TECHNOLOGY-SERVICES-LLC
85%
Under the MSA, CD8 agreed to provide us with access to specialized manufacturing facilities
DR-MANMOHAN-PATEL
DR-MANMOHAN-PATEL
85%
In December 2024, the Company contracted with Dr. Manmohan Patel to provide advisory services to the Company in support of the Company’s manufacturing development
PATEL-FAMILY
PATEL-FAMILY
85%
On June 6, 2024, we entered into the Loan Agreement, pursuant to which the Patel Family agreed to provide to us up to an initial amount of $36.0 million (the “Maximum Loan Amount”) under the Facility.
CRO
CRO
80%
in March 2026, we entered into a letter of intent to acquire a greater than 50% economic ownership stake in a company with a clinical research organization (CRO).
Reciprocal relationship from COHN graph: Reciprocal relationship from TVGN graph: Reciprocal relationship from COHN graph: sses) on CCM financial instruments received as non-cash consideration (4,312…
Tevogen Bio Holdings Inc. Customers
Ticker
Name
Confidence
Evidence
PATEL-FAMILY
PATEL-FAMILY
90%
On August 21, 2024, we entered into a securities purchase agreement with the Patel Family
KRHP-LLC
KRHP-LLC
80%
In January 2025, KRHP LLC granted the Company $2,000,000
DR-RYAN-SAADI
DR-RYAN-SAADI
75%
pursuant to which Merger Sub merged with and into Tevogen Bio (the “Merger”), with Tevogen Bio being the surviving company and a wholly
SEMPER-PARATUS-ACQUISITION-CORPORATION
SEMPER-PARATUS-ACQUISITION-CORPORATION
75%
pursuant to which Merger Sub merged with and into Tevogen Bio (the “Merger”), with Tevogen Bio being the surviving company and a wholly
SSVK-ASSOCIATES-LLC
SSVK-ASSOCIATES-LLC
75%
pursuant to which Merger Sub merged with and into Tevogen Bio (the “Merger”), with Tevogen Bio being the surviving company and a wholly
TEVOGEN-BIO-INC
TEVOGEN-BIO-INC
75%
pursuant to which Merger Sub merged with and into Tevogen Bio (the “Merger”), with Tevogen Bio being the surviving company and a wholly
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from TVGN graph: ny, and held various regional and global commercialization and alliance management roles at Hoechst Marion Roussel, …
SNYNF
Sanofi
72%
ny, and held various regional and global commercialization and alliance management roles at Hoechst Marion Roussel, Aventis, and then Sanofi-Aventis. 39 Item 1A. Risk Factors. RISK FACTORS Investing …
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
nt of our employee and executive compensation and retention strategy and will continue to impact our reported GAAP results in future periods. This non-GAAP measure should not be considered in isolati…
NATURE-OF-BUSINESS-TEVOGEN-BIO-HOLDINGS-INC
NATURE-OF-BUSINESS-TEVOGEN-BIO-HOLDINGS-INC
62%
d proceeds towards anticipated Series A-1 Preferred Stock Issuance - 3,000,000 Payment of offering costs associated with the sales agreement ( 100,000 ) - Proceeds from issuance of shares under the s…
SEMPER-MERGER-SUB-INC
SEMPER-MERGER-SUB-INC
62%
2023 (the “Merger Agreement”) by and among Semper Paratus Acquisition Corporation (“Semper Paratus”), Semper Merger Sub, Inc., a wholly owned subsidiary of Semper Paratus (“Merger Sub”), SSVK Associa…
Tevogen Bio Holdings Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TVGN-DEBT-13147
Warrants outstanding: 11817103
90%
xbrl warrant detail from xbrl 2025-12-31.
TVGN-DEBT-13148
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
TVGN-DEBT
Debt stack $9.5M
90%
Market cache reports total debt of $9.5M.
Tevogen Bio Holdings Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Tevogen Bio Holdings Inc..
Tevogen Bio Holdings Inc. Ownership
Holder
Name
Confidence
Evidence
TVGN-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 3 tracked holders.
Tevogen Bio Holdings Inc. Extended Supply Chain Network
